On December 9, 2025 CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation reported that data from two of its Investigational New Drug (IND) application enabling studies will be presented at the European Society for Medical Oncolgy (ESMO) (Free ESMO Whitepaper) Immuno-Oncology Congress 2025, taking place December 10-12, 2025 in London, United Kingdom.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CTO1681 is an orally administered immune modulator that targets inflammation in the tumor microenvironment and mitigates cell therapy induced toxicities frequently seen in lymphoma patients receiving CAR T-Cell Therapy. CytoAgents is currently enrolling patients in a Phase 1b/2a clinical trial evaluating CTO1681 in lymphoma patients receiving CAR T-Cell Therapy at risk for inflammatory driven toxicities.
At ESMO (Free ESMO Whitepaper), the company will present data from two non-clinical studies demonstrating that CTO1681 attenuates key cytokines known to drive Cytokine Release Syndrome (CRS) without compromising the CAR T-Cell mediated tumor killing in vitro and in vivo. These studies demonstrate that CTO1681 does not interfere with CD19 CAR T-Cell expansion and anti-tumor activity in vivo while reducing the inflammatory cytokines associated with CRS and ICANS.
"These data suggest CTO1681 could enable safer CAR T-Cell Therapy administration, support outpatient treatment paradigms and broaden patient access without compromising anti-tumor efficacy," said Teresa Whalen, Chief Executive Officer at CytoAgents. "We look forward to sharing these data at ESMO (Free ESMO Whitepaper) and to continuing our advancement of CTO1681."
Poster Presentation Details:
Title: CTO1681 Does Not Interfere with CAR T-Cell Anti-Tumor Efficacy In Vivo
Presenter: Michael Howell, PhD, Founder and President Mountaineer Biosciences, San Diego, CA, USA
Final Poster Number (FPN): 109P
Session Date and Time: Wednesday, December 10, 2025, 5:15 PM – 6:30 PM GMT
Location: Queen Elizabeth II Centre – Churchill Room
Title: CTO1681 Attenuates CRS-Driving Cytokines Without Compromising CAR T-Cell-Mediated Tumor Killing In Vitro
Presenter: Michael Howell, PhD, Founder and President Mountaineer Biosciences, San Diego, CA, USA
Final Poster Number (FPN): 113P
Session Date and Time: Wednesday, December 10, 2025, 5:15 PM – 6:30 PM GMT
Location: Queen Elizabeth II Centre – Churchill Room
(Press release, CytoAgents, DEC 9, 2025, View Source [SID1234661333])